

Optiscan Imaging Limited ABN: 81 077 771 987 ASX: OIL 10 October 2017

Zeiss/Optiscan collaboration unveils "Convivo"

ZEISS CONVIVO

Putting in-vivo cellular imaging at the surgeon's fingertips.





https://www.zeiss.com/meditec/int/products/neurosurgery/digital-biopsy-tool/convivo.html#zeiss-convivo

On 21 September 2017, Optiscan announced: "Carl Zeiss Meditec to unveil in vivo Digital Biopsy Tool". We are now delighted to announce that in Boston USA, Zeiss this week unveiled the collaboration product that Zeiss and Optiscan have been working to deliver - Zeiss Convivo.

The Convivo unit is a major medical breakthrough that will positively affect thousands of patients around the world. With FDA approval expected in early 2018, Convivo is validation of years of Optiscan development - the dream now becoming a commercial reality.

There are enormous benefits of the Convivo system in neurosurgery which include:

- For the first time neurosurgeons are able to perform a digital biopsy without the need for tissue extraction.
- The innovative Digital Biopsy Tool enables real-time visualisation of tissue microstructure and allows for checking a virtually unlimited number of samples throughout the operation.
- The ability to transfer and analyse digital images anytime and anywhere.

Optiscan is delighted to see the result of a number of years of effort come to fruition and look forward to this wonderful next step in the life span of the company.

For further information, please contact: Archie Fraser Chief Executive Officer